Edition of Prostaglandin E2 Receptors EP2 and EP4 by CRISPR/Cas9 Technology in Equine Adipose Mesenchymal Stem Cells.
CRISPR/cas9
adipose mesenchymal stem cell
equine
prostaglandin E2
Journal
Animals : an open access journal from MDPI
ISSN: 2076-2615
Titre abrégé: Animals (Basel)
Pays: Switzerland
ID NLM: 101635614
Informations de publication
Date de publication:
23 Jun 2020
23 Jun 2020
Historique:
received:
28
04
2020
revised:
10
06
2020
accepted:
11
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
27
6
2020
Statut:
epublish
Résumé
In mesenchymal stem cells (MSCs), it has been reported that prostaglandin E2 (PGE2) stimulation of EP2 and EP4 receptors triggers processes such as migration, self-renewal, survival, and proliferation, and their activation is involved in homing. The aim of this work was to establish a genetically modified adipose (aMSC) model in which receptor genes EP2 and EP4 were edited separately using the CRISPR/Cas9 system. After edition, the genes were evaluated as to if the expression of MSC surface markers was affected, as well as the migration capacity in vitro of the generated cells. Adipose MSCs were obtained from Chilean breed horses and cultured in DMEM High Glucose with 10% fetal bovine serum (FBS). sgRNA were cloned into a linearized LentiCRISPRv2GFP vector and transfected into HEK293FT cells for producing viral particles that were used to transduce aMSCs. GFP-expressing cells were separated by sorting to obtain individual clones. Genomic DNA was amplified, and the site-directed mutation frequency was assessed by T7E1, followed by Sanger sequencing. We selected 11 clones of EP2 and 10 clones of EP4, and by Sanger sequencing we confirmed 1 clone knock-out to aMSC/EP2 and one heterozygous mutant clone of aMSC/EP4. Both edited cells had decreased expression of EP2 and EP4 receptors when compared to the wild type, and the edition of EP2 and EP4 did not affect the expression of MSC surface markers, showing the same pattern in filling the scratch. We can conclude that the edition of these receptors in aMSCs does not affect their surface marker phenotype and migration ability when compared to wild-type cells.
Identifiants
pubmed: 32585798
pii: ani10061078
doi: 10.3390/ani10061078
pmc: PMC7341266
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : Postdoctoral Fellowship 3170390
Références
Eur J Immunol. 2016 Mar;46(3):677-88
pubmed: 26631603
Kidney Int. 2006 Sep;70(6):1099-106
pubmed: 16871242
Microbiology. 2005 Mar;151(Pt 3):653-663
pubmed: 15758212
Exp Cell Res. 2008 May 1;314(8):1831-8
pubmed: 18395713
Mol Med Rep. 2017 Jul;16(1):639-646
pubmed: 28560401
J Cell Physiol. 2012 Dec;227(12):3756-67
pubmed: 22378492
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell Med. 2012;4(1):1-11
pubmed: 23152950
J Clin Invest. 1999 Jun;103(11):1539-45
pubmed: 10359563
J Cell Physiol. 2011 Feb;226(2):559-71
pubmed: 20717968
Stem Cells Dev. 2018 Aug 1;27(15):1046-1052
pubmed: 29790424
Res Vet Sci. 2014 Feb;96(1):95-101
pubmed: 24377415
Contrast Media Mol Imaging. 2016 Nov;11(6):550-560
pubmed: 27976505
Lancet Neurol. 2012 Feb;11(2):150-6
pubmed: 22236384
Annu Rev Pharmacol Toxicol. 2001;41:661-90
pubmed: 11264472
Stem Cell Res Ther. 2018 Oct 25;9(1):288
pubmed: 30359315
Front Bioeng Biotechnol. 2020 Feb 05;8:43
pubmed: 32117924
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10501-6
pubmed: 10468638
Cell Death Dis. 2016 Jan 21;7:e2062
pubmed: 26794657
Stem Cell Res Ther. 2019 Dec 21;10(1):406
pubmed: 31864423
J Gene Med. 2019 Apr;21(4):e3082
pubmed: 30786106
J Biol Chem. 2007 Apr 20;282(16):11613-7
pubmed: 17329241
Annu Rev Biochem. 2000;69:145-82
pubmed: 10966456
Ocul Immunol Inflamm. 2006 Jun;14(3):157-63
pubmed: 16766399
Stem Cells. 2006 Apr;24(4):896-907
pubmed: 16339997
Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245
pubmed: 29762716
Prostaglandins Other Lipid Mediat. 2008 Jun;86(1-4):35-40
pubmed: 18406186
Stem Cells Int. 2017;2017:8178643
pubmed: 28740516
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Cancer Gene Ther. 2008 Apr;15(4):231-40
pubmed: 18202717
Gene. 2018 Jan 30;641:55-62
pubmed: 29031777
Mol Ther Methods Clin Dev. 2018 Aug 08;10:341-347
pubmed: 30191160
Stem Cells Transl Med. 2012 Dec;1(12):886-97
pubmed: 23283550
Microbiology. 2005 Aug;151(Pt 8):2551-2561
pubmed: 16079334
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
Gene Ther. 2006 Jun;13(12):991-4
pubmed: 16525481
Vet World. 2017 Nov;10(11):1361-1366
pubmed: 29263600
PLoS One. 2019 Mar 7;14(3):e0213376
pubmed: 30845180
J Neuroimmunol. 2011 Apr;233(1-2):106-11
pubmed: 21354631
Res Vet Sci. 2014 Dec;97(3):616-22
pubmed: 25443656
J Mol Evol. 2005 Feb;60(2):174-82
pubmed: 15791728
Cytotechnology. 2018 Apr;70(2):783-791
pubmed: 29387984
Mol Biotechnol. 2014 Aug;56(8):681-8
pubmed: 24870618
Reprod Domest Anim. 2009 Sep;44 Suppl 3:1-9
pubmed: 19660075
Theriogenology. 2011 May;75(8):1431-43
pubmed: 21196039
Hum Gene Ther. 2016 Aug;27(8):621-30
pubmed: 27158855
Stem Cells Dev. 2010 Feb;19(2):269-82
pubmed: 19604071
Blood. 2009 May 28;113(22):5444-55
pubmed: 19324903
Life Sci. 2003 Dec 5;74(2-3):143-53
pubmed: 14607241
Anim Reprod Sci. 2013 Nov 1;142(1-2):35-41
pubmed: 24035156
Mol Hum Reprod. 2006 Sep;12(9):577-85
pubmed: 16820403
Eur J Immunol. 2011 Oct;41(10):2840-51
pubmed: 21710489
J Leukoc Biol. 2019 Apr;105(4):705-717
pubmed: 30835912
Theriogenology. 2018 Jan 15;106:93-102
pubmed: 29049924
Sci Rep. 2016 May 27;6:26298
pubmed: 27230257
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Theriogenology. 2013 Mar 15;79(5):744-50
pubmed: 23270861
PLoS One. 2020 Feb 13;15(2):e0228910
pubmed: 32053639
Theriogenology. 2010 Sep 1;74(4):516-24
pubmed: 20071015
Stem Cell Res Ther. 2014 Feb 21;5(1):25
pubmed: 24559797
Jpn J Pharmacol. 2000 Aug;83(4):279-85
pubmed: 11001172
Sci Rep. 2018 Jan 17;8(1):888
pubmed: 29343825
Pharmacol Rev. 2007 Sep;59(3):207-24
pubmed: 17878511
Cytometry A. 2012 Apr;81(4):312-23
pubmed: 22411893